Tilrekimig cleared the EASI-75 primary endpoint in atopic dermatitis, Eric Simpson, MD confirmed in HCPLive coverage aired this week.

The drug hit a 75% reduction on the Eczema Area and Severity Index — the same regulatory benchmark that anchored dupilumab's pivotal program and now defines the bar for every targeted atopic dermatitis therapy in trials.

Simpson, one of the field's most prolific atopic dermatitis trialists, walked through the readout for HCPLive. His commentary carries weight: he's authored pivotal work on multiple AD biologics and has consulted across the wider pipeline, including JAK inhibitors and IL-13/IL-31 directed antibodies.

What does an EASI-75 hit mean in 2025?

EASI-75 has served as the workhorse primary endpoint for systemic atopic dermatitis since dupilumab's approval program. It now sets the regulatory floor for newer entrants — tralokinumab, lebrikizumab, upadacitinib, abrocitinib, and roflumilast among them.

A new EASI-75 readout doesn't automatically translate into clinical practice gains. Regulators and prescribers now weigh secondary metrics: Itch NRS, EASI-90, SCORAD, time to onset, durability, and the safety profile — particularly the infection, conjunctivitis, and lab-monitoring counts that have shaped the JAK and IL-13 classes.

What's missing from the public coverage so far?

The HCPLive segment doesn't yet disclose sample size, treatment duration, coprimary endpoints, or the absolute percentage of patients hitting EASI-75 in each arm. Without those numbers, head-to-head comparisons against dupilumab or lebrikizumab remain premature.

Simpson's commentary likely fills in several of those gaps. Dermatologists will still need to wait for a full peer-reviewed publication or the next major congress — AAD, EADV, AAAAI, or RAD — to see the complete efficacy table and adverse event counts.

Where does tilrekimig sit mechanistically?

Mechanism details weren't disclosed in the available coverage. The atopic dermatitis pipeline is crowded with IL-13, IL-31, IL-4 receptor, JAK, and TYK2 agents, so any new entrant needs a clean differentiation story — on efficacy, safety, dosing, or route of administration.

Where it goes from here

Another EASI-75 hit in atopic dermatitis extends a pattern the field has grown used to over the past five years. The real deciding factors now are durability, safety, and dosing convenience — the practical levers that drive formulary placement and step-therapy sequencing in real-world dermatology.

Watch for the full data set on a congress platform later this year.